Dr. J.J. Kiladjian at ASH 2017, Ropeginterferon Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients

[PVReporter]

Two Year Results from the First Prospective Randomized Controlled Trial -

pvreporter.com/dr-jean-jacq...

Hope you find the interview informative.

Best,

David Wallace - PV Reporter

[Bluetop]

It does seem that interferon is becoming the stronger option.

Thanks

[PVReporter in reply to Bluetop]

It would be my first choice, but all patients are different. This option should be discussed with your hematologist to weigh the pros and cons.